Dyno Therapeutics

Associate Director, Medical Science Liaison - Northeast, South, Central, or West Regions

Remote

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates must possess an advanced scientific degree, such as an MD, PhD, NP, PharmD, or PA, and a minimum of 8 years of experience as a Medical Science Liaison. Preferred experience includes clinical expertise in neuromuscular disorders, particularly DMD and DM1, and rare disease experience is considered. Strong knowledge of investigational products and the neuromuscular space, including emerging data, is required, along with an understanding of clinical trial and investigator-sponsored study processes.

Responsibilities

The Associate Director, Medical Science Liaison will build awareness of the company within the medical community and develop strategic KOL/territory engagement plans, support clinical research and speaker development, demonstrate thorough knowledge of the company’s portfolio, maximize conference attendance, collaborate cross-functionally to advance business and scientific goals, lead KOL engagement strategies, establish and develop HCP relationships through data discussions and addressing patient journey barriers, respond to information requests compliantly, manage administrative tasks, and leverage neuromuscular relationships to support study enrollment.

Skills

Medical Science
KOL engagement
Clinical Research
Medical Affairs
Scientific Communication
Strategic Planning
Therapeutic Knowledge
HCP engagement

Dyno Therapeutics

Develops AI-optimized gene therapy vectors

About Dyno Therapeutics

Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.

Key Metrics

Watertown, MassachusettsHeadquarters
2018Year Founded
$106MTotal Funding
SERIES_ACompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Remote Work Options

Risks

Gene therapy investment slowdown may impact Dyno's growth and innovation.
Manufacturing bottlenecks could hinder scaling of Dyno's operations.
Increased competition from companies like Form Bio challenges Dyno's market position.

Differentiation

Dyno uses AI to design optimized AAV vectors for gene therapy.
Their AI-driven CapsidMap platform enhances AAV vector development for muscle gene therapies.
Partnerships with major pharma companies like Astellas and Roche boost Dyno's market presence.

Upsides

AI-driven capsid design improves delivery efficiency and reduces manufacturing costs.
Collaboration with NVIDIA enhances biological sequence design for gene therapies.
Generative AI increases efficiency of eye and brain-targeted capsid delivery significantly.

Land your dream remote job 3x faster with AI